Scarica l'app Stockscreener
5.88
4.26%
0.24
Dopo l'orario di chiusura:
6.08
0.20
+3.40%
Alto Neuroscience Inc Borsa (ANRO) Ultime notizie
Relative strength of Alto Neuroscience Inc. in sector analysisJuly 2025 Market Mood & Advanced Technical Analysis Signals - newser.com
Will Alto Neuroscience Inc. stock recover faster than market2025 Breakouts & Breakdowns & Fast Entry and Exit Trade Plans - newser.com
What indicators show strength in Alto Neuroscience Inc.July 2025 Breakouts & Capital Protection Trading Alerts - newser.com
How risky is Alto Neuroscience Inc. stock now2025 Market Sentiment & Consistent Growth Equity Picks - newser.com
What earnings revisions data tells us about Alto Neuroscience Inc.Treasury Yields & Weekly Hot Stock Watchlists - newser.com
How to manage a losing position in Alto Neuroscience Inc.Forecast Cut & Smart Money Movement Alerts - newser.com
How to track smart money flows in Alto Neuroscience Inc.2025 Big Picture & Verified Entry Point Signals - newser.com
What MACD signals say about Alto Neuroscience Inc.Portfolio Gains Report & Stock Timing and Entry Methods - newser.com
Can Alto Neuroscience Inc. stock sustain free cash flow growthQuarterly Profit Review & Real-Time Buy Signal Notifications - newser.com
When is the best time to exit Alto Neuroscience Inc.Quarterly Portfolio Summary & Growth Oriented Trading Recommendations - newser.com
What the charts say about Alto Neuroscience Inc. today2025 Year in Review & Smart Money Movement Tracker - newser.com
What Fibonacci levels say about Alto Neuroscience Inc. reboundWeekly Risk Report & Free AI Powered Buy and Sell Recommendations - newser.com
Will Alto Neuroscience Inc. stock benefit from commodity supercycleQuarterly Portfolio Report & Smart Investment Allocation Insights - newser.com
Why Alto Neuroscience Inc. stock is a must watch in 2025Gold Moves & Fast Exit Strategy with Risk Control - newser.com
How to forecast Alto Neuroscience Inc. trends using time series2025 Price Targets & Safe Entry Trade Signal Reports - newser.com
Alto Neuroscience (NYSE:ANRO) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Alto Neuroscience Board Sued Over Study Result, 70% Stock Drop - Bloomberg Law News
Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders - GlobeNewswire
Alto Neuroscience Execs Sued Over Rosy Drug Claims - Law360
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
What drives Alto Neuroscience Inc stock priceSmall Cap Stock Opportunities & Outperform With Our Smart Trading Calculator - earlytimes.in
Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Is Alto Neuroscience Inc a good long term investmentOptions Trading Strategies & Free Tap Rapid Wealth - earlytimes.in
Optimistic Buy Rating for Alto Neuroscience, Inc. Amidst Promising Developments and FDA Fast Track Designation - TipRanks
Alto Neuroscience (ANRO): Evaluating Valuation After FDA Fast Track Milestone for Lead Schizophrenia Candidate - Yahoo Finance
Why retail traders accumulate Alto Neuroscience Inc. stock2025 Top Decliners & Intraday High Probability Alerts - newser.com
Alto Neuroscience: Evaluating Valuation After FDA Fast Track Win for ALTO-101 - simplywall.st
Alto Neuroscience Stock Soars Amid FDA Fast-Track Approval - StocksToTrade
Alto Neuroscience Stock Soars as FDA Grants Fast-Track for Schizophrenia Treatment - timothysykes.com
What moving averages say about Alto Neuroscience Inc.2025 Geopolitical Influence & Risk Controlled Daily Trade Plans - newser.com
Smart tools for monitoring Alto Neuroscience Inc.’s price actionJuly 2025 Trade Ideas & Verified Entry Point Detection - newser.com
Can Alto Neuroscience Inc. stock rebound after recent weaknessSell Signal & Smart Allocation Stock Tips - newser.com
Alto Neuroscience Soars After FDA Fast Track Decision - timothysykes.com
Alto Neuroscience Shares Rise After Getting FDA Fast-Track Designation - 富途牛牛
Rare Earth, Biotech, And Hotpot Stocks Steal The Show - Finimize
Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug - Stocktwits
Will Alto’s Innovative Research Drive its Market Surplus? - StocksToTrade
Alto Neuroscience stock soars after FDA grants Fast Track designation - Investing.com
Alto Neuroscience’s Schizophrenia Treatment Granted FDA Fast Track Designation - Contract Pharma
FDA grants fast track designation to Alto’s schizophrenia drug By Investing.com - Investing.com Australia
Alto Neuroscience receives FDA fast track designation for Alto-101 - MarketScreener
FDA grants fast track designation to Alto’s schizophrenia drug - Investing.com India
Alto Neuroscience granted fast track designation for ALTO-101 - TipRanks
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia | Fat Pitch Financials - FinancialContent
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia - The Joplin Globe
FY2025 Earnings Forecast for ANRO Issued By Chardan Capital - MarketBeat
Will Alto Neuroscience Inc. stock rally after Fed decisionsMarket Risk Analysis & Risk Controlled Swing Alerts - newser.com
Should you hold or exit Alto Neuroscience Inc. nowChart Signals & High Win Rate Trade Alerts - newser.com
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):